NCT04087460View on ClinicalTrials.gov

Phase Ⅰa Clinical Trial of a Pneumococcal Vaccine

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

April 10, 2020

Primary Completion Date

May 30, 2021

Study Completion Date

June 30, 2022

Conditions
PneumoniaRespiratory Tract DiseasesRespiratory Tract Infections
Interventions
BIOLOGICAL

Protein based pneumococcal vaccine(Low dose)

0.2mL,Intramuscular other name:PBPV

BIOLOGICAL

Protein based pneumococcal vaccine placebo(Low dose)

0.2mL,Intramuscular other name:PBPV placebo

BIOLOGICAL

Protein based pneumococcal vaccine(Middle dose)

0.5mL,Intramuscular other name:PBPV

BIOLOGICAL

Protein based pneumococcal vaccine placebo(Middle dose)

0.5mL,Intramuscular other name:PBPV placebo

BIOLOGICAL

Protein based pneumococcal vaccine(High dose)

1.0mL,Intramuscular other name:PBPV

BIOLOGICAL

Protein based pneumococcal vaccine placebo(High dose)

1.0mL,Intramuscular other name:PBPV placebo

Trial Locations (1)

450016

Suixian Center for Disease Control and Prevention, Shangqiu

Sponsors
All Listed Sponsors
collaborator

Henan Center for Disease Control and Prevention

OTHER_GOV

lead

CanSino Biologics Inc.

INDUSTRY

NCT04087460 - Phase Ⅰa Clinical Trial of a Pneumococcal Vaccine | Biotech Hunter | Biotech Hunter